Mostra i principali dati dell'item
Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)
dc.creator | Zitouni J., Bursztejn A.-C., Belloni Fortina A., Beauchet A., Di Lernia V., Lesiak A., Thomas J., Topkarci Z., Murashkin N., Brzezinski P., Torres T., Chiriac A., Luca C., McPherson T., Akinde M., Maruani A., Epishev R., Vidaurri de la Cruz H., Luna P.C., Amy de la Bretêque M., Lasek A., Bourrat E., Bachelerie M., Mallet S., Steff M., Bellissen A., Neri I., Zafiriou E., van den Reek J.M.P.A., Sonkoly E., Mahil S.K., Smith C.H., Flohr C., Bachelez H., Mahé E., the Groupe de Recherche sur le Psoriasis (GrPso) of the Societe Francaise de Dermatologie, the Groupe de recherche de la Societe Francaise de Dermatologie Pediatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BPSD), and the Societa Italiana di Dermatologia Pediatrica (S.I.Der.P.) | en |
dc.date.accessioned | 2023-01-31T11:38:43Z | |
dc.date.available | 2023-01-31T11:38:43Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.1111/jdv.18361 | |
dc.identifier.issn | 09269959 | |
dc.identifier.uri | http://hdl.handle.net/11615/81020 | |
dc.description.abstract | Background: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. Objectives: The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. Methods: We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. Results: One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). Discussion: Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children. © 2022 European Academy of Dermatology and Venereology. | en |
dc.language.iso | en | en |
dc.source | Journal of the European Academy of Dermatology and Venereology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85133816043&doi=10.1111%2fjdv.18361&partnerID=40&md5=daacd9083739e3dbda68e8718558a0b4 | |
dc.subject | adalimumab | en |
dc.subject | apremilast | en |
dc.subject | cyclosporine | en |
dc.subject | etanercept | en |
dc.subject | etretin | en |
dc.subject | methotrexate | en |
dc.subject | risankizumab | en |
dc.subject | secukinumab | en |
dc.subject | tumor necrosis factor inhibitor | en |
dc.subject | ustekinumab | en |
dc.subject | biological factor | en |
dc.subject | biological product | en |
dc.subject | methotrexate | en |
dc.subject | Article | en |
dc.subject | child | en |
dc.subject | controlled study | en |
dc.subject | coronavirus disease 2019 | en |
dc.subject | disease association | en |
dc.subject | disease course | en |
dc.subject | disease duration | en |
dc.subject | disease exacerbation | en |
dc.subject | disease registry | en |
dc.subject | disease severity | en |
dc.subject | disease severity assessment | en |
dc.subject | erythrodermic psoriasis | en |
dc.subject | female | en |
dc.subject | guttate psoriasis | en |
dc.subject | hospitalization | en |
dc.subject | human | en |
dc.subject | immunosuppressive treatment | en |
dc.subject | inverse psoriasis | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | medical history | en |
dc.subject | nail psoriasis | en |
dc.subject | palmoplantar plaque psoriasis | en |
dc.subject | pediatric patient | en |
dc.subject | phototherapy | en |
dc.subject | population research | en |
dc.subject | psoriasis | en |
dc.subject | psoriasis vulgaris | en |
dc.subject | psoriatic arthritis | en |
dc.subject | pustular psoriasis | en |
dc.subject | risk factor | en |
dc.subject | scalp psoriasis | en |
dc.subject | school child | en |
dc.subject | adolescent | en |
dc.subject | adult | en |
dc.subject | complication | en |
dc.subject | pandemic | en |
dc.subject | psoriasis | en |
dc.subject | register | en |
dc.subject | Adolescent | en |
dc.subject | Adult | en |
dc.subject | Biological Factors | en |
dc.subject | Biological Products | en |
dc.subject | Child | en |
dc.subject | COVID-19 | en |
dc.subject | Disease Progression | en |
dc.subject | Humans | en |
dc.subject | Methotrexate | en |
dc.subject | Pandemics | en |
dc.subject | Psoriasis | en |
dc.subject | Registries | en |
dc.subject | John Wiley and Sons Inc | en |
dc.title | Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry) | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |